These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 7579459)

  • 1. Increased glucose metabolism in untreated non-Hodgkin's lymphoma: a study with positron emission tomography and fluorine-18-fluorodeoxyglucose.
    Lapela M; Leskinen S; Minn HR; Lindholm P; Klemi PJ; Söderström KO; Bergman J; Haaparanta M; Ruotsalainen U; Solin O; Joensuu H
    Blood; 1995 Nov; 86(9):3522-7. PubMed ID: 7579459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uncoupling of fatty acid and glucose metabolism in malignant lymphoma: a PET study.
    Nuutinen J; Minn H; Bergman J; Haaparanta M; Ruotasalainen U; Laine H; Knuuti J
    Br J Cancer; 1999 May; 80(3-4):513-8. PubMed ID: 10408861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uptake of carbon-11-methionine and fluorodeoxyglucose in non-Hodgkin's lymphoma: a PET study.
    Leskinen-Kallio S; Ruotsalainen U; Någren K; Teräs M; Joensuu H
    J Nucl Med; 1991 Jun; 32(6):1211-8. PubMed ID: 2045935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence for a cardiac metabolic switch in patients with Hodgkin's lymphoma.
    Heckmann MB; Totakhel B; Finke D; Anker MS; Müller-Tidow C; Haberkorn U; Katus HA; Lehmann LH
    ESC Heart Fail; 2019 Aug; 6(4):824-829. PubMed ID: 31278857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of carbon-11 methionine positron emission tomography to assess malignancy grade and predict survival in patients with lymphomas.
    Nuutinen J; Leskinen S; Lindholm P; Söderström KO; Någren K; Huhtala S; Minn H
    Eur J Nucl Med; 1998 Jul; 25(7):729-35. PubMed ID: 9662595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of FDG-PET in the detection and management of malignant lymphoma: correlation of uptake with prognosis.
    Okada J; Yoshikawa K; Imazeki K; Minoshima S; Uno K; Itami J; Kuyama J; Maruno H; Arimizu N
    J Nucl Med; 1991 Apr; 32(4):686-91. PubMed ID: 2013808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of decreased uptake of 18F-fluorodeoxyglucose in the cerebral cortex of patients with intracranial non-Hodgkin's lymphoma lesions through PET/CT.
    Zhang Q; Tian T; Wang L; Qiu H; Li D
    Biomed Pharmacother; 2016 Dec; 84():1331-1336. PubMed ID: 27810790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Independent thallium-201 accumulation and fluorine-18-fluorodeoxyglucose metabolism in glioma.
    Oriuchi N; Tomiyoshi K; Inoue T; Ahmad K; Sarwar M; Tokunaga M; Suzuki H; Watanabe N; Hirano T; Horikoshi S; Shibasaki T; Tamura M; Endo K
    J Nucl Med; 1996 Mar; 37(3):457-62. PubMed ID: 8772644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of SUVmax measured by pretreatment 18F-FDG PET/CT in patients with primary gastric lymphoma.
    Hwang JP; Lim I; Byun BH; Kim BI; Choi CW; Lim SM
    Nucl Med Commun; 2016 Dec; 37(12):1267-1272. PubMed ID: 27482643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymphomatous involvement of gastrointestinal tract: evaluation by positron emission tomography with (18)F-fluorodeoxyglucose.
    Phongkitkarun S; Varavithya V; Kazama T; Faria SC; Mar MV; Podoloff DA; Macapinlac HA
    World J Gastroenterol; 2005 Dec; 11(46):7284-9. PubMed ID: 16437629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging.
    Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G
    Blood; 1999 Jul; 94(2):429-33. PubMed ID: 10397709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma.
    Torizuka T; Nakamura F; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Kobayashi M; Ouchi Y
    Eur J Nucl Med Mol Imaging; 2004 Jan; 31(1):22-8. PubMed ID: 14574514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased brain FDG uptake in patients with extensive non-Hodgkin's lymphoma lesions.
    Hanaoka K; Hosono M; Shimono T; Usami K; Komeya Y; Tsuchiya N; Yamazoe Y; Ishii K; Tatsumi Y; Sumita M
    Ann Nucl Med; 2010 Dec; 24(10):707-11. PubMed ID: 20824395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Standardised uptake value of 18F-FDG on staging PET/CT in newly diagnosed patients with different subtypes of non-Hodgkin's lymphoma.
    Papajík T; Mysliveček M; Sedová Z; Buriánková E; Procházka V; Koranda P; Raida L; Kubová Z; Palová M; Kučerová L; Flodr P; Jarkovský J; Dušek L; Indrák K
    Eur J Haematol; 2011 Jan; 86(1):32-7. PubMed ID: 20874822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Positron emission tomography with 18F-FDG compared with proliferative activity of tumor cells in different subtypes of non-Hodgkin lymphoma].
    Tiutin LA; Khodzsibekova MM; Pozharisskiĭ KM; Mukhina MS; Kostenikov NA; Il'in NV
    Vopr Onkol; 2011; 57(6):748-52. PubMed ID: 22416392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigating the existence of quantum metabolic values in non-Hodgkin's lymphoma by 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography.
    Wong CY; Thie J; Parling-Lynch KJ; Zakalik D; Wong RH; Gaskill M; Margolis JH; Hill J; Sukari A; Chundru S; Fink-Bennett D; Nagle C
    Mol Imaging Biol; 2007; 9(1):43-9. PubMed ID: 17176979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of PET-18FDG imaging in the clinical evaluation of head and neck lymphoma.
    Walsh RM; Wong WL; Chevretton EB; Beaney RP
    Clin Oncol (R Coll Radiol); 1996; 8(1):51-4. PubMed ID: 8688363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluorodeoxyglucose uptake in the bone marrow after granulocyte colony-stimulating factor administration in patients with non-Hodgkin's lymphoma.
    Hanaoka K; Hosono M; Usami K; Tatsumi Y; Yamazoe Y; Komeya Y; Tsuchiya N; Ishii K; Sumita M
    Nucl Med Commun; 2011 Aug; 32(8):678-83. PubMed ID: 21499162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDG-PET for predicting the prognosis of malignant lymphoma.
    Okada J; Oonishi H; Yoshikawa K; Itami J; Uno K; Imaseki K; Arimizu N
    Ann Nucl Med; 1994 Aug; 8(3):187-91. PubMed ID: 7811561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET.
    Torizuka T; Tamaki N; Inokuma T; Magata Y; Sasayama S; Yonekura Y; Tanaka A; Yamaoka Y; Yamamoto K; Konishi J
    J Nucl Med; 1995 Oct; 36(10):1811-7. PubMed ID: 7562048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.